Site Map
- FerGene announces Landmark Phase 3 study published in The Lancet Oncology
- FerGene announces pivotal Phase 3 study of nadofaragene firadenovec met its primary endpoint with more than half of patients with high-grade non-muscle invasive bladder cancer (CIS ± Ta/T1) achieving a complete response at three months
- FerGene Appoints David Meek Chief Executive Office
- FerGene Provides Update on BLA for Nadofaragene Firadenovec
- FerGene to present bladder cancer data at 2020 ASCO Genitourinary Cancers Symposium
- Ferring and Blackstone Life Sciences invest over $570 million USD in novel investigational gene therapy for bladder cancer patients
- New Analysis of Phase 3 study presented at SUO 2020
